2215 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for genetic diseases Animal model for Alzheimer's disease
Mouse Model For Alzheimer's Disease And Neurofibrillary Pathology
#2WILD-DERIVED MOUSE MODELS OF ALZHEIMER’S DISEASE
#3GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER’S DISEASE
#4A Beta Biomarker of Alzheimer’s Disease Model Mouse and Analysis Method Thereof
#5GENETICALLY MODIFIED MOUSE MODELS AND METHODS OF USE THEREOF
#6DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY
#7MODELS OF TAUOPATHY
#8Animal Model With Rapid Onset Of Alzheimer's Amyloid Beta Plaque Pathology
#9GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF
#10IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
#11IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
#12GENETICALLY ENGINEERED SWINE FOR PRECLINICAL VALIDATION
#13STEM-CELL BASED BIOMARKER DISCOVERY
#14METHOD FOR DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY USING HPMA
#15Models of tauopathy
#16A GENETICALLY MODIFIED IMMUNODEFICIENT MOUSE EXPRESSING HUMAN OR HUMANIZED APP AND MUTATED HUMAN PSEN1
#17Methods and compositions for modified factor IX fusion proteins
#18TISSUE SELECTIVE TRANSGENE EXPRESSION
#19NON-HUMAN ALZHEIMER'S DISEASE MODEL ANIMAL AND METHOD FOR PRODUCING SAME
#20PREPARATION METHOD FOR ANIMAL MODEL OF ALZHEIMER'S DISEASE AND ANIMAL MODEL OF ALZHEIMER'S DISEASE PREPARED BY THE SAME
#21NON-HUMAN PRIMATE ALZHEIMER'S DISEASE MODEL ANIMAL AND METHOD FOR PRODUCING SAME
#22ANIMAL MODEL FOR NEURODEGENERATIVE DISORDERS
#23APPLICATION OF TPK AS A TARGET IN ALZHEIMER'S DISEASE
#24COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME
#25Human Genomic Construct Reporter Cells and Mouse Models to Screen Therapeutics against Microglia-expressed Disease Associated Genes
#26DLGAP2 AS A THERAPEUTIC TARGET FOR AND ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE
#27A TRANSGENIC INVERTEBRATE MODEL FOR ALZHEIMER'S DISEASE AND USE THEREOF
#28GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
#29Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
#30Compositions and methods for characterizing a microbiome
#31Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain Injuries
#32ALZHEIMERS DISEASE ANIMAL MODEL AND USE THEREOF
#33Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy
#34METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY
#35TISSUE SELECTIVE TRANSGENE EXPRESSION
#36Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies
#37Genetically modified mouse expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof
#38Transgenic mice with inducible neuron-specific inactivation of HuR gene and method of screening
#39Late-onset Alzheimer's disease animal model and uses thereof
#40Transgenic mouse expressing amyloid precursor protein that has olfactory neuron degeneration
#41METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY
#42Method for screening drug and therapeutic targets used for treating Alzheimer's disease
#43Alzheimer's disease animal model
#44Transgenic mice expressing human TREM proteins and methods of use thereof
#45Visual stimuli maze test for detecting visual abnormalities in prodromal Alzheimer's disease and in Alzheimer's disease
#46Oncogenic Models Based on Delivery and Use of the CRISPR-Cas Systems, Vectors and Compositions
#47ANIMAL MODELS FOR BRAIN INFLAMMATION AND WHITE MATTER DEGENERATION
#48Methods and compositions for modified factor IX fusion proteins
#49Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
#50Method for treating a degenerative neurological disorders comprising administering ASM inhibitor
#51Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes
#52Methods and agents for treating Alzheimer's disease
#53Methods for the treatment and diagnosis of Alzheimer's disease and traumatic brain injuries
#54Antibodies to pyroglutamate amyloid-β and uses thereof
#55Transgenic mouse model for dementia
#56METHODS AND COMPOSITIONS TO TREAT AND DETECT MISFOLDED-SOD1 MEDIATED DISEASES
#57IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
#58Methods of treating cognitive impairment
#59COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE
#60Expression cassette and vector comprising Alzheimer's disease-related mutant genes and cell line transformed by means of same
#61Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#62Alzheimer's disease animal model
#63Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
#64Transgenic Animal Expressing Alzheimer's Tau Protein
#65Composition comprising ASM inhibitor as active ingredient for preventing or treating degenerative neurological disorders
#66Methods for diagnosis and treatment of amyotrophic lateral sclerosis based on an increased level of interaction between TDP-43 polypeptide and NF-KB P65 polypeptide
#67MODEL OF ALZHEIMER'S DISEASE
#68TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES
#69Methods and agents for treating Alzheimer's disease
#70Methods of treating cognitive impairment
#71TRANSGENIC MOUSE EXPRESSING HUMAN ISOGLUTAMINYL CYCLOTRANSFERASE
#72Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#73Transgenic comprising a human protein with a tendency to aggregate fused to a fluorescent protein
#74Biological complex specific for Alzheimer's disease detection in vitro and use thereof
#75Transgenic mouse model expressing amyloid β 4-42 peptide
#76Transgenic animal expressing Alzheimer's tau protein
#77Regulatory proteins and inhibitors
#78IN VIVO SCREENING MODELS FOR TREATMENT OF QC-RELATED DISORDERS
#79Assays of Neurodegenerative Disorders, including Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
#80PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY
#81METHOD OF TREATING NEURODEGENERATIVE DISEASE
#82TRANSGENIC ANIMAL MODEL OF NEURODEGENERATIVE DISORDERS
#83IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
#84Methods of treating cognitive impairment
#85Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#86Use of VEGF and homologues to treat neuron disorders
#87Mouse model for depression, schizophrenia and alzheimer's disease and the use thereof
#88Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#89ASSAYS OF NEURODEGENERATIVE DISORDERS, INCLUDING FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS
#90UBIQUILIN REGULATION OF PRESENILIN ENDOPROTEOLYSIS, AND SUPPRESSION OF POLYGLUTAMINE-INDUCED TOXICITY IN CELLS
#91Automated high-content live animal drug screening using
#92Targeting TGF-β as a therapy for Alzheimer's disease
#93USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
#94Transgenic animal model of neurodegenerative disorders
#95COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS
#96TRANSGENIC MAMALS MODIFIELD IN BRI PROTEIN EXPRESSION
#97HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCER
#98Animal model, and products and methods useful for the production thereof
#99CYP46A1 gene for the treatment of alzheimer's disease
#100GENOMIC EDITING OF GENES INVOLVED IN ALZHEIMER'S DISEASE
#101PRODUCTS AND THEIR USE FOR THE DIAGNOSIS, PREVENTION AND/OR CARE OF HUMAN AND/OR ANIMAL PATHOLOGIES CHARACTERISED BY THE ANOMALOUS DEPOSITION OF B-AMYLOID AND/OR AMYLOID-LIKE SUBSTANCE IN HUMAN AND/OR ANIMAL ORGANS AND TISSUES, AND SCREENING METHOD FOR DETERMINING THE RISK OF SUCH PATHOLOGIES
#102QUADRUPLE TRANSGENIC NON-HUMAN ANIMAL
#103MEMORY AND LEARNING IMPAIRMENTS ASSOCIATED WITH DISRUPTION OF EPHRIN RECEPTOR A6 (EphA6) GENE
#104MOUSE MODEL FOR DEPRESSION, SCHIZOPHRENIA AND ALZHEIMER'S DISEASE
#105MEANS AND METHODS FOR ISOLATING AND DETERMINING NOVEL TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS AND COMPOSITIONS COMPRISING THE SAME
#106ANIMAL MODEL SIMULATING NEUROLOGIC DISEASE
#107TRANSGENIC NON-HUMAN ANIMAL
#108Transgenic pig as a model of Alzheimer's disease
#109Truncated tau proteins
#110USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
#111Amyloid-beta polypeptide vaccine
#112Use of VEGF and homologues to treat neuron disorders
#113Mutants of Human App and Their Use for the Production of Transgenice Animals
#114Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
#115Transgenic pig model for a hereditary neurodegenerative autosomal dominant disease
#116Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
#117ALZHEIMER'S DISEASE ANIMAL MODEL, METHOD FOR OBTAINING SAME AND USES THEREOF
#118TEST AND MODEL FOR ALZHEIMER'S DISEASE
#119Methods for detecting the presence of mutant mammalian presenilin protein
#120Use of the ornithine transcarbamylase (), as a marker for diagnosing brain damages
#121Treatment of cerebral amyloid angiopathy
#122Transgenic animal model for alzheimer's disease
#123Non-invasive, in vivo fluorescent imaging of the nervous system in whole living animal
#124Transgenic mouse models of Aβ overexpression
#125Model of Alzheimer's Disease
#126Diagnostic and therapeutic target cdc2l6 proteins for neurodegenerative diseases
#127IDENTIFICATION OF NOVEL POST-TRANSLATIONAL PROTEIN MODIFICATIONS
#128ANIMAL MODELS FOR OBESITY AND NEURODEGENERATIVE DISEASES
#129Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease
#130Transgenic animal model of neurodegenerative disorders
#131Humanized anti-amyloid antibody
#132Antibody specific for mutant presenilin 2 and method of use thereof
#133Diagnostic and Therapeutic Use of the Kcne4 Gene and Protein for Alzheimer's Disease
#134Inducing neurofibrillary tangles in transgenic mice expressing a mutant tau protein
#135Methods and compositions to treat misfolded-SOD1 mediated diseases
#136Transgenic Zebrafish Models of Alzheimer's Disease
#137IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS
#138Transgenic Animal Models for Neurodevelopmental Disorders
#139Method for detecting candidate alzheimer's disease drug
#140Transgenic flies expressing tau and amyloid precursor fragment
#141Transgenic Mice Inducing Alzheimer's Disease Expressing Mutant Betactf99
#142Transgenic mice for screening for inhibitors of protein aggregation and methods for making and using them
#143Animal model of neurodegenerative diseases, the procedure for producing the model and applications thereof
#144MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION
#145Use of VEGF and homologuest to treat neuron disorders
#146Model mouse of Alzheimer's disease expressing FAD APP 716 and use thereof
#147Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#148Non-human animal alzheimer's disease model and uses thereof
#149GENERATION OF ANIMAL MODELS
#150Use of VEGF and homologues to treat neuron disorders
#151Monitoring APP cleavage in transgenic rodents comprising an APP Swedish mutation
#152Methods for treating progressive neurodegenerative disorders
#153Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
#154Transgenic mouse expressing an APP 670/671 mutation
#155Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases
#156PROCESS FOR IDENTIFICATION OF NOVEL DISEASE BIOMARKERS IN MOUSE MODELS OF ALZHEIMER'S DISEASE INCLUDING TRIPLE TRANSGENIC MICE AND PRODUCTS THEREBY
#157HUMAN DISEASE MODELING USING SOMATIC GENE TRANSFER
#158TRANSGENIC MICE COMPRISING A GENOMIC HUMAN TAU TRANSGENE
#159Invertebrate animal model with neurodegenerative phenotype for screening and testing substances
#160Transgenic mouse having an amyloid precursor protein with a modified beta secretase cleavage site
#161Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
#162Peptide having hydrolase activity
#163Tau hyperphosphorylation in transgenic mice expressing the APP double mutation
#164Diagnostic and therapeutic use of a rab family gtp-binding protein for neurodegenerative diseases
#165Non-transgenic rodent model of Alzheimer's disease
#166Receptor
#167Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
#168Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
#169Non-naturally occurring animal that expresses an untranslated non-coding RNA
#170Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype
#171Protecting cell therapy for neurological disorders including Parkinson's disease
#172Transgenic animals as models for neurodegenerative disease
#173Truncated tau proteins
#174Imaging modalities for screening Alzheimer's disease therapeutics
#175Transgenic animal expressing alzheimer's tau protein
#176Methods for the identification of compounds for the treatment of Alzheimer's disease
#177Diagnostic and therapeutic use of a voltage-gated ion channel scn2a for neurodegenerative diseases
#178Treatment of neurodegenerative conditions with nimesulide
#179Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors
#180An invertebrate animal model with neurodegenerative phenotype for screening and testing substances
#181Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
#182Compositions and methods for producing and using homogenous neuronal cell transplants
#183Diagnostic and therapeutic use of an atp-binding cassette gene and protein for neurodegenerative diseases
#184RAAV-neprilysin compositions and methods of use
#185Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer' s disease
#186Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
#187Antibody specific for mutant presenilin 1
#188Modulation of brain pathways and function
#189Cell cultures from animal models of Alzheimer's disease for screening and testing drug efficacy
#190Novel method for down-regulation of amyloid
#191Test and model for Alzheimer's disease
#192Transgenic flies expressing Abeta42-Italian
#193Transgenic flies expressing Abeta42-Dutch
#194Transgenic flies expressing Abeta42-Flemish
#195Transgenic flies expressing Abeta42-Iowa
#196Transgenic flies expressing Abeta42-Arctic
#197Model for neurodegenerative disorders
#198Transgenic flies expressing Abeta42-Italian
#199Animal model simulating neurologic disease
#200Increased and sustained in vivo gene expression using a nucleic acid, histone and amphipathic compound composition
#201P2x7 receptor-deficient non-human animals and uses thereof
#202Transgenic animals exhibiting major disorders related to Alzheimer's disease
#203Mouse showing neurofibril change due to senile dementia
#204Monitoring APP cleavage in transgenic rodents comprising an APP-Swedish mutation
#205Triple transgenic mouse model of Alzheimer's disease
#206Method of inducing the formation of neurofibrillary tangles in transgenic animals
#207Method of screening for compounds that modulate activity of a regulatory sequence of the β-2 subunit of a neuronal nicotinic acetylcholine receptor